How has the BA.2.12.1 COVID-19 subvariant changed clinical practice?
Real-World Best Practices in a COVID-19 Clinic
Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.
Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.
Dougan M, Azizad M, Chen P, et al. medRxiv. 2022. [Epub ahead of print]
Hachmann NP, Miller J, Collier A-rY, et al. medRxiv. 2022. [Epub ahead of print]
Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.
Levin M, Ustianowski A, De Wit S, et al. N Engl J Med. 2022. [Epub ahead of print]
Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.
Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.
Wu EL, Kumar RN, Moore WJ, et al. J Gen Intern Med. 2022:1-9.
Yu J, Collier A-RY, Rowe M, et al. N Engl J Med. 2022;386(16):1579-1580.
Current Evidence and Guidelines for Anti-SARS-CoV-2 Monoclonal Antibodies
|Faculty:||Monica Gandhi, MD, MPH; Lucy Horton, MD, MPH|